Literature DB >> 21545478

Plasma vaspin concentrations are elevated in metabolic syndrome in men and are correlated with coronary atherosclerosis in women.

Sung Hee Choi1, Soo Heon Kwak, Yenna Lee, Min Kyung Moon, Soo Lim, Young Joo Park, Hak C Jang, Min Seon Kim.   

Abstract

OBJECTIVE: Vaspin is visceral adipose-tissue-derived adipokine, which has an insulin-sensitizing effect in obese type 2 diabetic rodent models. As adipokines may serve as a link between visceral adiposity and atherosclerosis, we investigated whether plasma vaspin concentrations were associated with the metabolic syndrome and coronary atherosclerosis. DESIGN AND METHODS: We measured fasting plasma vaspin levels in 81 subjects with the metabolic syndrome and 241 age- and sex-matched control subjects without the metabolic syndrome using the enzyme-linked immunosorbent assay. Multi-detector row cardiac computed tomography was performed to evaluate coronary atherosclerosis. We analysed sex-specific plasma vaspin concentrations according to the presence of the metabolic syndrome and the severity of coronary atherosclerosis.
RESULTS: Plasma vaspin concentrations were significantly higher in men with the metabolic syndrome compared with those without the metabolic syndrome [median 0·60 (inter-quartile range 0·40-0·99) ng/ml vs 0·40 (0·26-0·66) ng/ml, P = 0·002]. There was a positive correlation between plasma vaspin concentrations and body mass index, waist circumference, and per cent body fat in men. However, these relationships were not found in women. Plasma vaspin concentrations were associated with the presence and severity of coronary artery stenosis such as higher Agatstone calcium score, number of diseased vessels and characteristics of coronary artery plaque only in women.
CONCLUSIONS: Higher plasma vaspin concentrations are significantly associated with metabolic syndrome in men. In women, vaspin concentrations are associated with coronary atherosclerosis. Further studies regarding the role of vaspin in the pathogenesis of obesity and atherosclerosis are required.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21545478     DOI: 10.1111/j.1365-2265.2011.04095.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  25 in total

1.  Comparative analysis of vaspin in pregnant women with and without gestational diabetes mellitus and healthy non-pregnant women.

Authors:  Xiaojiao Jia; Shuyi Wang; Ning Ma; Xiaojing Li; Likui Guo; Xiaoli Liu; Tao Dong; Yali Liu; Qiang Lu
Journal:  Endocrine       Date:  2014-06-15       Impact factor: 3.633

2.  Mediatory effect of circulating vaspin on resting metabolic rate in obese individuals.

Authors:  Sajjad Moradi; Khadijeh Mirzaei; Ahmed Abdulahi Abdurahman; Seyed Ali Keshavarz; Arash Hossein-Nezhad
Journal:  Eur J Nutr       Date:  2015-06-10       Impact factor: 5.614

3.  The relationship between circulating adiponectin, leptin and vaspin with bone mineral density (BMD), arterial calcification and stiffness: a cross-sectional study in post-menopausal women.

Authors:  N Tanna; K Patel; A E Moore; D Dulnoan; S Edwards; G Hampson
Journal:  J Endocrinol Invest       Date:  2017-06-23       Impact factor: 4.256

4.  Epidemiology of micro- and macrovascular complications of type 2 diabetes in Korea.

Authors:  Jung Hee Kim; Dae Jung Kim; Hak Chul Jang; Sung Hee Choi
Journal:  Diabetes Metab J       Date:  2011-12-26       Impact factor: 5.376

Review 5.  The role of vaspin in the development of metabolic and glucose tolerance disorders and atherosclerosis.

Authors:  Rumyana Dimova; Tsvetalina Tankova
Journal:  Biomed Res Int       Date:  2015-04-06       Impact factor: 3.411

6.  Crosstalk between circulating peroxisome proliferator-activated receptor gamma, adipokines and metabolic syndrome in obese subjects.

Authors:  Khadijeh Mirzaei; Arash Hossein-Nezhad; Seyed Ali Keshavarz; Fariba Koohdani; Ali Akbar Saboor-Yaraghi; Saeed Hosseini; Mohammad Reza Eshraghian; Mahmoud Djalali
Journal:  Diabetol Metab Syndr       Date:  2013-12-12       Impact factor: 3.320

7.  Vaspin increases nitric oxide bioavailability through the reduction of asymmetric dimethylarginine in vascular endothelial cells.

Authors:  Chang Hee Jung; Woo Je Lee; Jenie Yoonoo Hwang; Min Jung Lee; So Mi Seol; Yun Mi Kim; Yoo La Lee; Hyun Sik Kim; Min-Seon Kim; Joong-Yeol Park
Journal:  PLoS One       Date:  2012-12-28       Impact factor: 3.240

8.  Clinical implications of adipocytokines and newly emerging metabolic factors with relation to insulin resistance and cardiovascular health.

Authors:  Sung Hee Choi; Eun Shil Hong; Soo Lim
Journal:  Front Endocrinol (Lausanne)       Date:  2013-08-21       Impact factor: 5.555

9.  Role of serum vaspin in progression of type 2 diabetes: a 2-year cohort study.

Authors:  Weixia Jian; Wenhui Peng; Sumei Xiao; Hailing Li; Jie Jin; Li Qin; Yan Dong; Qing Su
Journal:  PLoS One       Date:  2014-04-14       Impact factor: 3.240

10.  Vaspin inhibits cytokine-induced nuclear factor-kappa B activation and adhesion molecule expression via AMP-activated protein kinase activation in vascular endothelial cells.

Authors:  Chang Hee Jung; Min Jung Lee; Yu Mi Kang; Yoo La Lee; Hae Kyeong Yoon; Sang-Wook Kang; Woo Je Lee; Joong-Yeol Park
Journal:  Cardiovasc Diabetol       Date:  2014-02-12       Impact factor: 9.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.